Recurrent GBM Brain Tumors with Few Mutations Respond Best to Immunotherapy
Updated
Written By
![Headshot of Sarah Avery](/sites/default/files/styles/home_small_cards/public/2023-08/SarahAvery.png?itok=iDOtuZtk)
Sarah Avery
Director, Duke Health News Office
Related News
![NewsMention_CristieFelix](/sites/default/files/styles/blog_events_featured/public/image_123650291%20%281%29.jpg?itok=xuzf3d9C)
Duke Neurosurgery
![Ines Batinic Haberle hold up a vial of BMX-001 in her lab](/sites/default/files/styles/blog_events_featured/public/Blog_batinic_haberle_lab.jpg?itok=Nw0j1l0C)
Duke University School of Medicine
Related News
![NewsMention_CristieFelix](/sites/default/files/styles/blog_events_featured/public/image_123650291%20%281%29.jpg?itok=xuzf3d9C)
Duke Neurosurgery
![Ines Batinic Haberle hold up a vial of BMX-001 in her lab](/sites/default/files/styles/blog_events_featured/public/Blog_batinic_haberle_lab.jpg?itok=Nw0j1l0C)
Duke University School of Medicine